Keith Crandell

Background

Keith Crandell is a co-founder and Managing Director of ARCH Venture Partners. He focuses on life science therapeutics, tools, devices, diagnostics, specialty materials, electronics, and photonics. Key investments include 908 Devices, Twist Bioscience (TWST), Quanterix (QTRX), and Vizgen. He holds an MBA from the University of Chicago, an MS in Chemistry from the University of Texas at Arlington, and a BS in Chemistry and Mathematics from St. Lawrence University. Prior to ARCH, he was with specialty chemical firm Hercules Inc.

Investment Focus

Notable Investments

Twist Bioscience

NASDAQ: TWST

Quanterix

NASDAQ: QTRX

908 Devices

NASDAQ: MASS